Navigation Links
GeneCards(R) Version 3.0 Beta Released
Date:5/13/2009

CAMBRIDGE, Mass., May 13 /PRNewswire/ -- Xennex, Inc. (Xennex) announced today a major leap for GeneCards(R) with the release of Version 3.0 beta, available at http://www.genecards.org/v3.

The new GeneCards Version 3.0 features a significantly upgraded infrastructure, including a comprehensive relational biological database, and a novel, sophisticated and speedier search engine. It provides capabilities for highly effective and well-targeted queries, a user-friendly display and clear data navigation. Also released is a preliminary version of GeneDecks Version 3, which makes use of the new GeneCards relational database for complex analyses on sets of genes.

Dr. David Warshawsky, President and CEO of Xennex, stated: "We are delighted to see the outstanding progress resulting from our partnership with the GeneCards team at the Weizmann Institute of Science. GeneCards Version 3.0 is a major milestone that will enable users around the world to better perform cutting-edge research in various fields of biology and medicine, and in the discovery and development of diagnostics and therapeutics."

Xennex is providing its commercial users with access to the new GeneCards Version 3.0 beta relational database. With GeneCards Version 3.0, Xennex' customers will be able to integrate GeneCards data into their internal systems, and perform comprehensive data mining.

About GeneCards(R)

GeneCards(R) (http://www.genecards.org/) is a searchable, integrated database of human genes that provides concise genomic, transcriptomic, genetic, proteomic, functional and disease-related information on all known and predicted human genes. Information is featured in 18 GeneCards sections and includes orthologies, disease relationships, mutations and SNPs, gene expression, gene function, pathways, protein-protein interactions, related drugs & compounds and direct links to valuable research reagents and tools such as antibodies, recombinant proteins, clones, expression assays and RNAi reagents. GeneCards was developed over the last 12 years by a world-leading bioinformatics team at the Weizmann Institute of Science in Israel, directed by Marilyn Safran and by Professor Doron Lancet of the Department of Molecular Genetics, Head of the Crown Human Genome Center, and the incumbent of the Ralph & Lois Silver Professorial Chair of Human Genomics at the Weizmann Institute of Science.

About Xennex

Founded in 2003, Xennex, Inc. (http://www.xennexinc.com) is a dynamic privately held company that is dedicated to providing Biotechnology, Pharmaceutical and other life sciences companies, as well as organizations dealing with biotechnology intellectual property, the highest level of services and tools to enhance their gene-based research. Xennex' products help such organizations to optimize their efforts to develop innovative medical products and services. Xennex' customers include many of the world's leading biotech and pharmaceutical companies and organizations dealing with intellectual property, located in North America, Europe and Japan. Xennex' products are used in hundreds of commercial and academic organizations by tens of thousands of users around the globe.

    For further information, please contact:

    Xennex, Inc.
    David Warshawsky, Ph.D.
    Chief Executive Officer
    Tel: +1 617 497 7774
    davidw@xennexinc.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Xennex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Xennex Inc. Providing Satoris Inc. with Latest GeneCards(R) Tools for Characterization of Protein Biomarkers Associated With Neurological Conditions
2. Japan Patent Office Licenses GeneCards(R) from Xennex, Inc.
3. Cyprotex Launches Cloe(R) Gateway, its Secure web Portal for Access to Cyprotex Services Including an Enhanced Version of Cloe(R) PK.
4. ChemAxon Launches Marvin and JChem Version 5.2; Web Services, native .NET API, Homology Groups, 3D Alignment and Structural Frameworks
5. Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft
6. Delaware Court Rules That Watson Does Not Infringe Patent Related to Generic Version of Concerta(R) and Declares Patent Invalid
7. SAFC Biosciences(TM) Completes Conversion of Lenexa Media Milling Facility to Animal Component Free
8. PHARMORX Security Introduces New Technology Solutions for Counterfeiting, Grey Market Diversion, Track & Trace
9. Bio-Tech Medical Software, Inc. Biometrics Joins Forces with the University of Central Florida to Fight Diversion and Help Combat Prescription Narcotic Drug Abuse
10. Medicsight Unveils New Version of ColonCAD(TM) at ECR 2009
11. ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)...   Boston Biomedical , an industry leader in ... stemness pathways, today presented data from two clinical studies ... American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium ... In a Phase Ib/II study of napabucasin – ... stemness pathways by targeting STAT3 – colorectal cancer (CRC) ...
(Date:1/20/2017)... Stock-Callers.com explores the Biotech industry ... most recent performances of select equities. In this morning,s ... ), Abeona Therapeutics Inc. (NASDAQ: ABEO ), ... Sage Therapeutics Inc. (NASDAQ: SAGE ). According ... global Biotech market size is expected to reach $604.40 billion by 2020 due ...
(Date:1/20/2017)... NEW YORK , January 20, 2017 ... Health Organization, cancer is one of leading causes of ... in 2012. Although the number of cancer related deaths ... since 1990. Rising in incidence rate of various cancers ... According to a research report by Global Market Insights, ...
(Date:1/19/2017)... Research and Markets has announced the addition of the ... Global Opportunity Analysis and Industry Forecast, 2014-2022" report to their ... Cancer ... reach $15,737 million by 2022 from $6,521 in 2015, growing at ... Omic technologies segment accounted for more than half of the revenue ...
Breaking Biology Technology:
(Date:1/11/2017)... MOINES, Iowa , Jan. 11, 2017 ... industry first with the release of its patent-pending calibration ... quickly and reliably perform calibrations, securely upload data logs ... flexibility for the customer. "Fighting drunk driving ... only for the public at large, but also for ...
(Date:1/6/2017)... 2017  SomaLogic announced today that it has ... by iCarbonX, the China -based ... Digital Health Ecosystem that can define each person,s ... biological, behavioral and psychological data, the Internet and ... SomaLogic will provide proteomics data and applications expertise ...
(Date:1/4/2017)... VEGAS , Jan. 4, 2017  CES ... performance biometric sensor technology, today announced the launch ... sensor systems, the highly-accurate biometric sensor modules ... biometric technology, experience and expertise. The two ... Benchmark designed specifically for hearables, and Benchmark BW2.0, ...
Breaking Biology News(10 mins):